High sensitivity detection of EGFR exon 20 T790M and C797S mutations using ICE COLD-FOR

被引：0
|
作者：
Wu, Grant
Jensen, Sheena
Scott, Karissa
Montagne, Erin
Stoddard, Jason
Krzycki, Phil
Schweikart, Courtney
Legendre, Benjamin L.
Eastlake, Philip
Richardson, Katherine A.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1390
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
    Lu, Xiaoyun
    Yu, Lei
    Zhang, Zhang
    Ren, Xiaomei
    Smaill, Jeff B.
    Ding, Ke
    MEDICINAL RESEARCH REVIEWS, 2018, 38 (05) : 1550 - 1581
  • [22] Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
    Wang, X.
    Gao, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S922 - S923
  • [23] Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation
    Zhang, Hualin
    Xie, Ruliang
    AI-furas, Hawaa
    Li, Yupeng
    Wu, Qingxia
    Li, Jian
    Xu, Fang
    Xu, Tianfeng
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (02): : 278 - 283
  • [24] EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
    Rangachari, Deepa
    To, Ciric
    Shpilsky, Jason E.
    VanderLaan, Paul A.
    Kobayashi, Susumu S.
    Mushajiang, Mierzhati
    Lau, Christie J.
    Paweletz, Cloud P.
    Oxnard, Geoffrey R.
    Janne, Pasi A.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 1995 - 2002
  • [25] CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
    Kashima, Kenji
    Kawauchi, Hiroki
    Tanimura, Hiromi
    Tachibana, Yukako
    Chiba, Takashi
    Torizawa, Takuya
    Sakamoto, Hiroshi
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2288 - 2297
  • [26] The concomitant EGFR T790M/C797S in trans and cis in three osimertinib-resistant lung adenocarcinoma patients.
    Liu, Chunling
    Li, Jidong
    Liu, Hailong
    Du, Rong
    Fang, Nan
    Zhang, Jingbo
    Tang, Yu
    Wang, Jianwei
    Wu, Qixi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Overcoming the C797S/T790M mutation mediated Osimertinib resistance by Brigatinib combined with anti-EGFR antibody.
    Uchibori, Ken
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2018, 109 : 568 - 568
  • [28] Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
    Enrico, Diego
    Tsou, Florencia
    Catani, Greta
    Pupareli, Carmen
    Girotti, Maria Romina
    Alvarez, David Esteban Ulloa
    Waisberg, Federico
    Rodriguez, Andres
    Reyes, Roxana
    Chacon, Matias
    Reguart, Noemi
    Martin, Claudio
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [29] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
    Arulananda, Surein
    Do, Hongdo
    Musafer, Ashan
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1728 - 1732
  • [30] Brigatinib/cetuximab/osimertinibChemotherapy resistance secondary to C797S mutation in cis with T790M: case report
    Reactions Weekly, 2019, 1753 (1) : 81 - 81
12345